acquired
Stage
2
Investors
About
KaNDy Therapeutics is a UK-based clinical-stage company focused on optimizing the potential of NT-814, a first-in-class, non-hormonal treatment for postmenopausal vasomotor symptoms, as an alternative to hormone replacement therapy.
Explore KaNDy Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.